Buntinx A - Search Results

1

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.

Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR, Pryor JS, Buntinx A, Holmes IB, Chao YS, Bolognese JA. Tobert JA, et al. Among authors: buntinx a. J Clin Invest. 1982 Apr;69(4):913-9. doi: 10.1172/jci110530. J Clin Invest. 1982. PMID: 6918402 Free PMC article. Clinical Trial.

2

Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio.

Tobert JA, Cirillo VJ, Hitzenberger G, James I, Pryor J, Cook T, Buntinx A, Holmes IB, Lutterbeck PM. Tobert JA, et al. Among authors: buntinx a. Clin Pharmacol Ther. 1981 Mar;29(3):344-50. doi: 10.1038/clpt.1981.47. Clin Pharmacol Ther. 1981. PMID: 7471605 Clinical Trial.

3

Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states.

Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntinx AP, Meisinger MA, Huber PB, Hall TL, Yeh KC. Tobert JA, et al. Among authors: buntinx ap. Clin Pharmacol Ther. 1981 Sep;30(3):385-9. doi: 10.1038/clpt.1981.177. Clin Pharmacol Ther. 1981. PMID: 7023791 Clinical Trial.

4

Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men.

Depré M, Meeter C, Van Hecken A, Laskin OL, Buntinx A, De Schepper PJ. Depré M, et al. Among authors: buntinx a. Clin Pharmacol Ther. 1992 Oct;52(4):409-12. doi: 10.1038/clpt.1992.163. Clin Pharmacol Ther. 1992. PMID: 1424413 Clinical Trial.

5

Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic.

Verbeeck RK, Boel A, Buntinx A, De Schepper PJ. Verbeeck RK, et al. Among authors: buntinx a. Biochem Pharmacol. 1980 Feb 15;29(4):571-6. doi: 10.1016/0006-2952(80)90378-0. Biochem Pharmacol. 1980. PMID: 7370051 No abstract available.

6

Lack of interaction between famotidine and warfarin.

De Lepeleire I, Van Hecken A, Verbesselt R, Tjandra-Maga TB, Buntinx A, Distlerath L, De Schepper PJ. De Lepeleire I, et al. Among authors: buntinx a. Int J Clin Pharmacol Res. 1990;10(3):167-71. Int J Clin Pharmacol Res. 1990. PMID: 2228341

7

Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.

Depre M, Friedman B, Tanaka W, Van Hecken A, Buntinx A, DeSchepper PJ. Depre M, et al. Among authors: buntinx a. Clin Pharmacol Ther. 1993 May;53(5):602-7. doi: 10.1038/clpt.1993.76. Clin Pharmacol Ther. 1993. PMID: 8387904 Clinical Trial.

8

Absence of a pharmacokinetic interaction between enalapril and frusemide.

Van Hecken AM, Verbesselt R, Buntinx A, Cirillo VJ, De Schepper PJ. Van Hecken AM, et al. Among authors: buntinx a. Br J Clin Pharmacol. 1987 Jan;23(1):84-7. doi: 10.1111/j.1365-2125.1987.tb03013.x. Br J Clin Pharmacol. 1987. PMID: 3028456 Free PMC article. Clinical Trial.

9

Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.

Depré M, Margolskee DJ, Hsieh JY, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, De Schepper PJ. Depré M, et al. Among authors: buntinx a. Eur J Clin Pharmacol. 1992;43(4):427-30. doi: 10.1007/BF02220621. Eur J Clin Pharmacol. 1992. PMID: 1451725 Clinical Trial.

10

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Van Hecken A, et al. Among authors: buntinx a. J Clin Pharmacol. 2000 Oct;40(10):1109-20. J Clin Pharmacol. 2000. PMID: 11028250 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters